Showing results (11-20 of 85) with videos related to
Sort By:
Pageof 9
Clinical Breast Cancer|October 28, 2008
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature reviewRodabe N Amaria, John R Corboy, Christina A Finlayson, et al.Cancer Biology & Medicine|January 23, 2015
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanomaTeresa Kim, Rodabe N Amaria, Christine Spencer, et al.Cytotherapy|March 25, 2025
Entering a new era of tumor-infiltrating lymphocyte cell therapy innovationRodabe N Amaria, Krishna V Komanduri, Adam J Schoenfeld, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 28, 2023
Neoadjuvant Immunotherapy in Melanoma: The Paradigm ShiftTina J Hieken, Firas Kreidieh, Veronica Aedo-Lopez, et al.Melanoma Research|August 18, 2017
Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastasesIsabella C Glitza, Nandita Guha-Thakurta, Neil M D'Souza, et al.Cancer Immunology, Immunotherapy : CII|September 28, 2013
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patientsKimberly R Jordan, Rodabe N Amaria, Oscar Ramirez, et al.Immunity|January 1, 2026
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicityMinke W Lucas, Elizabeth M Burton, Petros Dimitriadis, et al.Journal of Translational Medicine|June 15, 2022
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021Elizabeth M Burton, Rodabe N Amaria, Tina Cascone, et al.Cancer|October 29, 2019
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case seriesKourtney Holbrook, Jose Lutzky, Michael A Davies, et al.Nuclear Medicine Communications|October 7, 2015
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaRonald J Schmitt, Sarah M Kreidler, Deborah H Glueck, et al.Pageof 9